Antiretroviral therapy (ART) is a combination of medications that stops HIV from replicating inside the body. It doesn’t cure HIV, but it suppresses the virus to such low levels that a person can live a normal lifespan, protect their immune system, and eliminate the risk of transmitting HIV to sexual partners. ART is recommended for everyone diagnosed with HIV, ideally starting the same day or as soon as possible after diagnosis.
How ART Stops HIV From Replicating
HIV works by hijacking immune cells called CD4 cells, using them as factories to make copies of itself, and destroying them in the process. Left untreated, the virus gradually dismantles the immune system. ART interrupts this process by blocking the virus at multiple stages of its life cycle simultaneously, which is why treatment always combines drugs from at least two different classes.
The virus goes through several steps to reproduce: it attaches to a CD4 cell, fuses with the cell’s outer membrane, converts its genetic material from RNA into DNA, inserts that DNA into the cell’s own genome, and then uses the cell’s machinery to assemble new copies of itself. Each drug class targets a specific step. Some drugs prevent the virus from entering the cell at all. Others block the enzyme that converts viral RNA to DNA. Others stop the virus from stitching its DNA into the host cell’s genome. Still others interfere with the final assembly of new virus particles.
Because ART attacks multiple stages at once, it’s extremely difficult for HIV to develop workarounds against all the drugs simultaneously. This is why single-drug treatment was never effective and why combination therapy transformed HIV from a fatal diagnosis into a manageable condition.
The Goal: Undetectable Viral Load
The primary target of ART is to reduce the amount of virus in the blood (called viral load) to undetectable levels, generally defined as fewer than 20 copies per milliliter. Most people reach this threshold within a few months of starting treatment. Below 200 copies per milliliter, treatment is still considered successful, though the ideal is as low as the lab can measure.
As the virus is suppressed, the immune system begins to recover. CD4 cell counts typically rise by 50 to 150 cells per cubic millimeter in the first year, with the fastest gains in the first three months. After that, counts continue climbing by roughly 50 to 100 cells per year until they stabilize. This recovery is what protects against the opportunistic infections that define AIDS.
Reaching and maintaining an undetectable viral load also has a profound implication for transmission. The CDC states that a person living with HIV who maintains an undetectable viral load has zero risk of transmitting HIV to sexual partners. This principle, known as U=U (Undetectable = Untransmittable), is backed by large studies tracking thousands of couples where one partner was HIV-positive and virally suppressed, with no linked transmissions observed.
Starting Treatment
Current U.S. and international guidelines recommend starting ART immediately after diagnosis, or as close to it as possible. This “rapid start” approach has been shown to be safe and effective, and it improves the chances that someone will stay connected to care and achieve viral suppression quickly. Even people diagnosed during acute (very recent) HIV infection benefit from same-day initiation.
The shift toward immediate treatment represents a major change from earlier decades, when doctors often waited until CD4 counts dropped below certain thresholds. The evidence now clearly shows that earlier treatment preserves more immune function, prevents complications, and reduces transmission at the population level. With early diagnosis and prompt ART, life expectancy for people with HIV now matches that of the general population.
What Daily Treatment Looks Like
Most people take ART as a single pill once a day. Modern regimens combine two or three active drugs into one tablet, which simplifies what used to be a handful of pills taken multiple times daily. The most commonly prescribed first-line regimens are built around a class of drugs that blocks HIV from inserting its DNA into host cells (integrase inhibitors), combined with drugs that prevent the virus from converting its RNA to DNA.
For people who prefer not to take daily pills, a long-acting injectable option became available in 2021. This regimen, sold under the brand name Cabenuva, involves two injections given by a healthcare provider once a month. A dosing schedule of once every two months has also shown comparable effectiveness in clinical trials. These injections are an option for people who have already achieved viral suppression on oral therapy.
Why Adherence Matters
Taking ART consistently is critical. When doses are missed, the virus gets opportunities to replicate. During replication, HIV mutates rapidly, and some of those mutations can make the virus resistant to one or more drugs in the regimen. Once resistance develops, those medications stop working, and treatment options narrow.
For people who anticipate difficulty sticking to a daily schedule, clinicians typically choose regimens with a high genetic barrier to resistance. These drugs require the virus to accumulate multiple mutations before they lose effectiveness, which provides a wider margin of safety if a dose is occasionally missed. But no regimen is bulletproof against sustained poor adherence. Setting a daily routine, using reminders, and addressing barriers like side effects, mental health challenges, or housing instability all improve long-term success.
Side Effects: Short and Long Term
Modern ART regimens are far better tolerated than earlier generations of HIV drugs, but they aren’t free of side effects. In the first few weeks, some people experience nausea, headaches, fatigue, or trouble sleeping. These initial effects usually fade as the body adjusts.
Long-term use introduces subtler concerns. People living with HIV on ART have higher rates of certain metabolic conditions compared to the general population, including type 2 diabetes, kidney disease, and fatty liver disease. Metabolic syndrome, a cluster of risk factors involving blood sugar, cholesterol, and abdominal fat, has been reported in 11% to 45% of people with HIV depending on the study. Some of this excess risk comes from the virus itself and the chronic inflammation it causes, but certain drug classes contribute as well. Longer cumulative use of some older drugs in the NRTI class has been linked to roughly double the risk of developing diabetes compared to no use.
Bone density loss is another consideration. People with HIV face higher rates of osteoporosis and fractures as they age, partly independent of treatment. However, specific older formulations have been associated with additional bone mineral density decline. Newer versions of these drugs appear to be gentler on bones and kidneys, which is one reason treatment guidelines have shifted toward them.
Because ART is a lifelong commitment, monitoring is part of the process. Viral load is checked regularly to confirm the drugs are working, and CD4 counts are tracked during the first couple of years. Once someone is stably suppressed with healthy immune counts, the monitoring schedule relaxes. Routine bloodwork also watches for metabolic changes so they can be addressed early.
ART as Prevention
Beyond treating people already living with HIV, antiretroviral drugs play a central role in prevention. Pre-exposure prophylaxis (PrEP) uses one or two of the same drug classes to protect HIV-negative people from acquiring the virus. Post-exposure prophylaxis (PEP) is a 28-day course of ART taken after a potential exposure. And the principle of U=U means that effective treatment of HIV-positive individuals is itself one of the most powerful prevention tools available, reducing new infections across entire communities.
This dual role, both treatment and prevention, is why public health campaigns emphasize not just access to ART but rapid initiation and sustained viral suppression. Every person who reaches and maintains an undetectable viral load is both protecting their own health and breaking the chain of transmission.